Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

SEK advanced against EUR, after the release of a report about the values of three different indicators, which measure the consumers and business confidence in Sweden. All of them had beaten the analysts forecasts.

EUR/SEK reached a session low at 8.8794, at 9:45 GMT, the lowest since November the 12-th. Support was likely to be received at November 12-th low, at 8.7956, while resistance was to be encountered at November 21-st high, 8.9657.

An index measuring consumer confidence in Sweden in November showed a reading of 104.9 today, compared with an estimate of 102. The manufacturing confidence reading was 105.8, compared with an estimate of 100.6, while the third indicator the Economic Tendency Survey, mostly comparable to Europes Economic Sentiment Indicator (ESI), also exceeded the analysts expectations, reaching 104.1, compared to a predicted value of 101.8.

Earlier last month, the Swedish Central Bank decided to keep the main interest rate at 1 percent and to postpone its intentions of tightening monetary policy until late next year, when the prospects for the Swedish economy improve. According to Riksbank in a statement made on October 24-th, the GDP of the largest Nordic economy (Sweden) is expected to grow 2.6 percent next year, compared to 0.7 percent until the end of the year.

Meanwhile, Andreas Wallstrom, an economist at Nordea Bank AB in Stockholm, cited by Bloomberg, said that “Swedish consumers see that happy days are coming and households became more optimistic both on their own economy and the overall Swedish economy”.

Elsewhere, USD/SEK was losing 0.82% on a daily basis to trade at 6.5783 at 14:53 GMT. The pound was little changed against the euro, with EUR/GBP cross ticking up a mere 0.01% to trade at 0.8347 at 13:11 GMT, while GBP/USD climbed to a daily high at 1.6141 at 12:10 GMT, after which consolidation followed at 1.6131, rising 0.16% for the day.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • USD/CAD Hits Lowest Level in Over a Year on CAD StrengthUSD/CAD Hits Lowest Level in Over a Year on CAD Strength Key Moments USD/CAD trades near 1.3500, down about 0.40%, marking its weakest level since October 2024. West Texas Intermediate (WTI) crude climbs to $65.90 per barrel, its highest level since September 26, rising more than 4% […]
  • Forex Market: EUR/AUD daily forecastForex Market: EUR/AUD daily forecast During yesterday’s trading session EUR/AUD traded within the range of 1.4399-1.4464 and closed at 1.4421, losing 0.2% for the day.At 6:29 GMT today EUR/AUD was losing 0.25% for the day to trade at 1.4386. The pair touched a daily low at […]
  • Singapore manufacturing production growth slows markedlySingapore manufacturing production growth slows markedly Singapore’s manufacturing output has increased at an annualized rate of 9.8% in September, while slowing sharply from a 22% YoY rise in August.Still, the latest data far exceeded market consensus of a 3.5% growth.In September, […]
  • Raiffeisen share price down, sees second annual loss in 2015Raiffeisen share price down, sees second annual loss in 2015 Austrias Raiffeisen Bank projected on Wednesday another full-year loss as the company intends to book the majority of its planned restructuring costs in the year ahead.Europes second-largest bank confirmed a loss of €493 million for the […]
  • Forex Market: GBP/CAD daily trading forecastForex Market: GBP/CAD daily trading forecast Yesterday’s trade saw GBP/CAD within the range of 1.9198-1.9328. The pair closed at 1.9260, losing 0.11% on a daily basis.At 8:54 GMT today GBP/CAD was down 0.17% for the day to trade at 1.9230. The cross touched a daily low at 1.9217 at […]
  • Pfizer Inc.’s share price down, to buy rights to a cancer drug of Merck at the price of $850 millionPfizer Inc.’s share price down, to buy rights to a cancer drug of Merck at the price of $850 million Pfizer Inc. is to pay $850 million for rights to a cancer drug, developed by Merck KGaA. The deal is to grant Pfizer the opportunity to get an experimental treatment such as the one it looked for when it made its takeover bid for Astrazeneca […]